<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473434</url>
  </required_header>
  <id_info>
    <org_study_id>CR013213</org_study_id>
    <secondary_id>R076477SCH3021</secondary_id>
    <nct_id>NCT00473434</nct_id>
  </id_info>
  <brief_title>An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia</brief_title>
  <official_title>An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the dose distribution, effectiveness and safety in
      patients with schizophrenia who are switched from an oral atypical antipsychotic to
      Paliperidone ER. In this study patients and physicians know the name and the dose of the
      study drug. Newly diagnosed patients will also be included in the study. In general, the
      recommended Paliperidone ER dose will be 6 mg once daily, however some patients may require a
      higher or lower initial dose in the recommended range of 3 to 12 mg once daily. The dose can
      be adjusted any point during the study, to a maximum dose of 12mg/day. Flexible dosing was
      chosen to best mimic actual clinical practice.The safety assessments to be conducted
      throughout this study including the regular monitoring and recording of all Adverse Events
      and Serious Adverse Events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a non-randomised (both patient and physician know the study drug), single arm,
      open label multicentre study which is aimed to evaluate the dose distribution, efficacy and
      safety in patients with schizophrenia who are switched from an oral atypical antipsychotic to
      Paliperidone ER. Newly diagnosed patients will also be included in the study. In general, the
      recommended Paliperidone ER dose will be 6 mg once daily, however some patients may require a
      higher or lower initial dose in the recommended range of 3 to 12 mg once daily. The dose can
      be adjusted any point during the study, to a maximum dose of 12mg/day. Flexible dosing was
      chosen to best mimic actual clinical practice.The study duration will be split into two
      phases. Phase A will be 12 weeks and Phase B which will be an optional follow up phase will
      be 40 weeks. Assessment of efficacy and safety will be performed in Phase A at baseline, 2,
      4, 6, 9 and 12 weeks and in Phase B at 20, 28, 36, 44 and 52 weeks. At the first visit, a
      full psychiatric history, demographic data and physical examination will be undertaken.
      Throughout the study, the following procedures, documentations and evaluations will be
      performed: descriptions of concomitant medications; hospitalisations for psychiatric reasons;
      clinical deterioration; Clinical Global Impression - Severity (CGI-S) and Global Assessment
      of Functioning (GAF) assessments; Community Treatment Order (CTO) status; weight; adherence
      and adverse event reporting. Physical examinations will be performed periodically.
      Paliperidone ER OROS will be supplied in 3 mg, 6 mg, and 9 mg tablets for oral
      administration. In general, the recommended Paliperidone ER dose will be 6 mg once daily,
      however some patients may require a higher or lower initial dose in the recommended range of
      3 to 12 mg once daily. The dose can be adjusted any point during the study, to a maximum dose
      of 12mg/day. The study duration will be split into two phases. Phase A will be 12 weeks and
      Phase B which will be an optional follow up phase
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Mean Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 1 to Day 84</measure>
    <time_frame>Day 1 to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Median Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 1 to Day 84</measure>
    <time_frame>Day 1 to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Mean Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 57 to Day 84</measure>
    <time_frame>Day 57 to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Median Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 57 to Day 84</measure>
    <time_frame>Day 57 to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Mean Overall Average Daily-prescribed Dose of Paliperidone Extended Release (ER) From Week 0 to Week 12</measure>
    <time_frame>Week 0 to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Median Overall Average Daily-prescribed Dose of Paliperidone Extended Release (ER) From Week 0 to Week 12</measure>
    <time_frame>Week 0 to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Clinical Global Impression of Severity (CGI-S) Throughout the Study</measure>
    <time_frame>52 weeks</time_frame>
    <description>The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to &quot;Normal, not at all ill&quot; and a rating of 7 is equivalent to &quot;Among the most extremely ill patients&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Global Assessment of Functioning (GAF) Throughout the Study</measure>
    <time_frame>52 Weeks</time_frame>
    <description>The GAF is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants Presenting Clinical Deterioration Throughout the Study</measure>
    <time_frame>52 Weeks</time_frame>
    <description>This Outcome Measure is intended to document only the hospitalizations associated with clinical deterioration, ie, when the patient needs to be hospitalized due to exacerbation of psychotic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Hospitalizations Throughout the Study</measure>
    <time_frame>52 Weeks</time_frame>
    <description>This outcome measure is intended to document all hospitalizations that occurred throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Length of Hospitalizations Throughout the Study</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paliperidone3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone</intervention_name>
    <description>3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must satisfy the following criteria to be eligible for this study: patients
             with diagnoses of schizophrenia according to the DSM-IV criteria including newly
             diagnosed patients

          -  Out-patients or in-patients with expected discharge within 8 weeks

          -  Patients or their legally acceptable representatives must have signed an informed
             consent document indicating that they understand the purpose of and procedures
             required for the study and are willing to participate in the study.

        Exclusion Criteria:

          -  Patients who meet any of the following criteria will be excluded from participating in
             the study: patients who are resistant to antipsychotic treatment

          -  Patients who have been on clozapine or long-acting injectable antipsychotic medication
             during the last 3 months

          -  Patients with CGl-S scores &gt; 6 or who who have been hospitalized for longer than 8
             continuous weeks during the past 6 months

          -  Pregnant or breast-feeding females

          -  Patients with a history or current symptoms of tardive dyskinesia or neuroleptic
             malignant syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag Pty Ltd Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag Pty Ltd</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=236&amp;filename=CR013213_CSR.pdf</url>
    <description>An open label multicentre study to determine the dose distribution of Paliperidone ER OROSÂ® in patients with schizophrenia</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2007</study_first_submitted>
  <study_first_submitted_qc>May 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2007</study_first_posted>
  <results_first_submitted>June 26, 2012</results_first_submitted>
  <results_first_submitted_qc>September 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 8, 2012</results_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Treatment Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paliperidone Extended Release (ER)</title>
          <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient was selling medication to others</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety evaluation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ceased in favor of Paliperidone</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switching to trial medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer required</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paliperidone Extended Release (ER)</title>
          <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.0" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Mean Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 1 to Day 84</title>
        <time_frame>Day 1 to Day 84</time_frame>
        <population>Intent-To-Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone Extended Release (ER)</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 1 to Day 84</title>
          <population>Intent-To-Treat (ITT) population</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Median Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 1 to Day 84</title>
        <time_frame>Day 1 to Day 84</time_frame>
        <population>Intent-To-Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone Extended Release (ER)</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 1 to Day 84</title>
          <population>Intent-To-Treat (ITT) population</population>
          <units>mg</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Mean Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 57 to Day 84</title>
        <time_frame>Day 57 to Day 84</time_frame>
        <population>Intent-To-Treat (ITT) population, excluding participants no longer participating in the study at Day 57</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone Extended Release (ER)</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 57 to Day 84</title>
          <population>Intent-To-Treat (ITT) population, excluding participants no longer participating in the study at Day 57</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Median Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 57 to Day 84</title>
        <time_frame>Day 57 to Day 84</time_frame>
        <population>Intent-To-Treat (ITT) population, excluding participants no longer participating in the study at Day 57</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone Extended Release (ER)</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Modal Prescribed Daily Dose of Paliperidone Extended Release (ER) From Day 57 to Day 84</title>
          <population>Intent-To-Treat (ITT) population, excluding participants no longer participating in the study at Day 57</population>
          <units>mg</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Mean Overall Average Daily-prescribed Dose of Paliperidone Extended Release (ER) From Week 0 to Week 12</title>
        <time_frame>Week 0 to Week 12</time_frame>
        <population>Intent-To-Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone Extended Release (ER)</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Overall Average Daily-prescribed Dose of Paliperidone Extended Release (ER) From Week 0 to Week 12</title>
          <population>Intent-To-Treat (ITT) population</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Median Overall Average Daily-prescribed Dose of Paliperidone Extended Release (ER) From Week 0 to Week 12</title>
        <time_frame>Week 0 to Week 12</time_frame>
        <population>Intent-To-Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone Extended Release (ER)</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Median Overall Average Daily-prescribed Dose of Paliperidone Extended Release (ER) From Week 0 to Week 12</title>
          <population>Intent-To-Treat (ITT) population</population>
          <units>mg</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3.6" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Clinical Global Impression of Severity (CGI-S) Throughout the Study</title>
        <description>The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to &quot;Normal, not at all ill&quot; and a rating of 7 is equivalent to &quot;Among the most extremely ill patients&quot;.</description>
        <time_frame>52 weeks</time_frame>
        <population>All participants with evaluable data at each measurement time point</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Week 2</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Week 4</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Week 6</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Week 9</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O6">
            <title>Week 12</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O7">
            <title>Week 20</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O8">
            <title>Week 28</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O9">
            <title>Week 36</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O10">
            <title>Week 44</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O11">
            <title>Week 52</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Clinical Global Impression of Severity (CGI-S) Throughout the Study</title>
          <description>The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a patient. A rating of 1 is equivalent to &quot;Normal, not at all ill&quot; and a rating of 7 is equivalent to &quot;Among the most extremely ill patients&quot;.</description>
          <population>All participants with evaluable data at each measurement time point</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="17"/>
                <count group_id="O11" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.2"/>
                    <measurement group_id="O2" value="3.3" spread="1.1"/>
                    <measurement group_id="O3" value="3.2" spread="1.0"/>
                    <measurement group_id="O4" value="3.1" spread="1.1"/>
                    <measurement group_id="O5" value="2.8" spread="1.0"/>
                    <measurement group_id="O6" value="2.8" spread="1.0"/>
                    <measurement group_id="O7" value="2.9" spread="1.1"/>
                    <measurement group_id="O8" value="2.7" spread="1.1"/>
                    <measurement group_id="O9" value="2.7" spread="0.8"/>
                    <measurement group_id="O10" value="2.9" spread="1.2"/>
                    <measurement group_id="O11" value="2.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Global Assessment of Functioning (GAF) Throughout the Study</title>
        <description>The GAF is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.</description>
        <time_frame>52 Weeks</time_frame>
        <population>All participants with evaluable data at each measurement time point</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Week 2</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Week 4</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Week 6</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Week 9</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O6">
            <title>Week 12</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O7">
            <title>Week 20</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O8">
            <title>Week 28</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O9">
            <title>Week 36</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O10">
            <title>Week 44</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O11">
            <title>Week 52</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Global Assessment of Functioning (GAF) Throughout the Study</title>
          <description>The GAF is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.</description>
          <population>All participants with evaluable data at each measurement time point</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="17"/>
                <count group_id="O11" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" spread="14.7"/>
                    <measurement group_id="O2" value="58.9" spread="15.0"/>
                    <measurement group_id="O3" value="63.9" spread="15.3"/>
                    <measurement group_id="O4" value="63.9" spread="15.6"/>
                    <measurement group_id="O5" value="66.3" spread="13.8"/>
                    <measurement group_id="O6" value="65.4" spread="14.6"/>
                    <measurement group_id="O7" value="65.1" spread="14.7"/>
                    <measurement group_id="O8" value="71.1" spread="13.3"/>
                    <measurement group_id="O9" value="71.6" spread="14.9"/>
                    <measurement group_id="O10" value="69.0" spread="17.2"/>
                    <measurement group_id="O11" value="63.3" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants Presenting Clinical Deterioration Throughout the Study</title>
        <description>This Outcome Measure is intended to document only the hospitalizations associated with clinical deterioration, ie, when the patient needs to be hospitalized due to exacerbation of psychotic symptoms.</description>
        <time_frame>52 Weeks</time_frame>
        <population>All participants with evaluable data at each measurement time point</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Week 2</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Week 4</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Week 6</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Week 9</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O6">
            <title>Week 12</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O7">
            <title>Week 20</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O8">
            <title>Week 28</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O9">
            <title>Week 36</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O10">
            <title>Week 44</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O11">
            <title>Week 52</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Presenting Clinical Deterioration Throughout the Study</title>
          <description>This Outcome Measure is intended to document only the hospitalizations associated with clinical deterioration, ie, when the patient needs to be hospitalized due to exacerbation of psychotic symptoms.</description>
          <population>All participants with evaluable data at each measurement time point</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="17"/>
                <count group_id="O11" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospitalized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="14.7"/>
                    <measurement group_id="O2" value="5.3" spread="15.0"/>
                    <measurement group_id="O3" value="13.5" spread="15.3"/>
                    <measurement group_id="O4" value="5.9" spread="15.6"/>
                    <measurement group_id="O5" value="7.1" spread="13.8"/>
                    <measurement group_id="O6" value="3.2" spread="14.6"/>
                    <measurement group_id="O7" value="3.7" spread="14.7"/>
                    <measurement group_id="O8" value="0" spread="13.3"/>
                    <measurement group_id="O9" value="0" spread="14.9"/>
                    <measurement group_id="O10" value="0" spread="17.2"/>
                    <measurement group_id="O11" value="12.5" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Care Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="3.6"/>
                    <measurement group_id="O6" value="3.2"/>
                    <measurement group_id="O7" value="7.4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="5.9"/>
                    <measurement group_id="O11" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Violent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self Injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3.2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Hospitalizations Throughout the Study</title>
        <description>This outcome measure is intended to document all hospitalizations that occurred throughout the study.</description>
        <time_frame>52 Weeks</time_frame>
        <population>All participants with evaluable data at each measurement time point</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Week 2</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Week 4</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Week 6</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Week 9</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O6">
            <title>Week 12</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O7">
            <title>Week 20</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O8">
            <title>Week 28</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O9">
            <title>Week 36</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O10">
            <title>Week 44</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O11">
            <title>Week 52</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Hospitalizations Throughout the Study</title>
          <description>This outcome measure is intended to document all hospitalizations that occurred throughout the study.</description>
          <population>All participants with evaluable data at each measurement time point</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="27"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="17"/>
                <count group_id="O11" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="14.7"/>
                    <measurement group_id="O2" value="2" spread="15.0"/>
                    <measurement group_id="O3" value="6" spread="15.3"/>
                    <measurement group_id="O4" value="2" spread="15.6"/>
                    <measurement group_id="O5" value="3" spread="13.8"/>
                    <measurement group_id="O6" value="1" spread="14.6"/>
                    <measurement group_id="O7" value="1" spread="14.7"/>
                    <measurement group_id="O8" value="0" spread="13.3"/>
                    <measurement group_id="O9" value="0" spread="14.9"/>
                    <measurement group_id="O10" value="1" spread="17.2"/>
                    <measurement group_id="O11" value="2" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Length of Hospitalizations Throughout the Study</title>
        <time_frame>52 weeks</time_frame>
        <population>Participants who were hospitalized and had evaluable data at each measurement time point</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Week 2</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Week 4</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Week 6</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Week 9</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O6">
            <title>Week 12</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O7">
            <title>Week 20</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O8">
            <title>Week 44</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
          <group group_id="O9">
            <title>Week 52</title>
            <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Length of Hospitalizations Throughout the Study</title>
          <population>Participants who were hospitalized and had evaluable data at each measurement time point</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="11.5"/>
                    <measurement group_id="O2" value="66" spread="0"/>
                    <measurement group_id="O3" value="7.3" spread="6.0"/>
                    <measurement group_id="O4" value="28.0" spread="5.7"/>
                    <measurement group_id="O5" value="179.0" spread="220.6"/>
                    <measurement group_id="O6" value="34" spread="0"/>
                    <measurement group_id="O7" value="19" spread="0"/>
                    <measurement group_id="O8" value="4" spread="0"/>
                    <measurement group_id="O9" value="20.5" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paliperidone Extended Release (ER)</title>
          <description>Paliperidone ER 3mg or 6mg or 9mg or 12mg once daily for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA SOC</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Mental disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Schizophrenia exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA SOC</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Regional Medical Affairs Therapeutic Lead Immunol</name_or_title>
      <organization>Jan-Cil Australia</organization>
      <phone>61 2 88753219</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

